

**PPARG Blocking Peptide (N-term)**  
**Synthetic peptide**  
**Catalog # BP20705a****Specification**

---

**PPARG Blocking Peptide (N-term) - Product Information**Primary Accession [P37231](#)**PPARG Blocking Peptide (N-term) - Additional Information****Gene ID** 5468**Other Names**

Peroxisome proliferator-activated receptor gamma, PPAR-gamma, Nuclear receptor subfamily 1 group C member 3, PPARG, NR1C3

**Target/Specificity**

The synthetic peptide sequence is selected from aa 2-15 of HUMAN PPARG

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**PPARG Blocking Peptide (N-term) - Protein Information****Name** PPARG**Synonyms** NR1C3**Function**

Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE) and modulates the transcription of its target genes, such as acyl-CoA oxidase. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis. ARF6 acts as a key regulator of the tissue-specific adipocyte P2 (aP2) enhancer. Acts as a critical regulator of gut homeostasis by suppressing NF-kappa-B-mediated pro-inflammatory responses. Plays a role in the regulation of cardiovascular circadian rhythms by regulating the transcription of BMAL1 in the blood vessels (By similarity).

**Cellular Location**

Nucleus. Cytoplasm. Note=Redistributed from the nucleus to the cytosol through a MAP2K1/MEK1-dependent manner. NOCT enhances its nuclear translocation

**Tissue Location**

Highest expression in adipose tissue. Lower in skeletal muscle, spleen, heart and liver. Also detectable in placenta, lung and ovary.

**PPARG Blocking Peptide (N-term) - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

**PPARG Blocking Peptide (N-term) - Images****PPARG Blocking Peptide (N-term) - Background**

Nuclear receptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the nuclear receptor binds to DNA specific PPAR response elements (PPRE) and modulates the transcription of its target genes, such as acyl-CoA oxidase. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis. ARF6 acts as a key regulator of the tissue-specific adipocyte P2 (aP2) enhancer. Acts as a critical regulator of gut homeostasis by suppressing NF-kappa-B-mediated proinflammatory responses.

**PPARG Blocking Peptide (N-term) - References**

Mukherjee R.,et al.J. Biol. Chem. 272:8071-8076(1997).  
Elbrecht A.,et al.Biochem. Biophys. Res. Commun. 224:431-437(1996).  
Yanase T.,et al.Biochem. Biophys. Res. Commun. 233:320-324(1997).  
Greene M.E.,et al.Gene Expr. 4:281-299(1995).  
Greene M.E.,et al.Submitted (DEC-2001) to the EMBL/GenBank/DDBJ databases.